Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-004695-18 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Federal Ministry of Health, Germany (Bundesministerium für Gesundheit, BMG) | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This study is a 4-arm, multicenter, randomized, partly double- blind, controlled trial to evaluate the safety and efficacy of convalescent serum (CP) or camostat mesylate with control or placebo in adult patients diagnosed with SARS-CoV-2 and high risk for moderate/severe COVID-19. The working hypothesis to be tested in the RES-Q-HR study is that the early use of convalescent plasma (CP) or camostat mesylate (Foipan®) reduces the likelihood of disease progression to modified WHO stages 4b-8 in SARS-CoV-2 positive adult patients at high risk of moderate or severe COVID-19 progression. The primary endpoint of the study is the cumulative number of individuals who progressed to or beyond category 4b on the modified WHO (World Health Organization) COVID-19 ordinal scale within 28 days after randomization.
The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This trial focusses on SARS-CoV-2 positive patients with pre-existing risk factors for a moderate or severe COVID-19 disease course. This study is a 4-arm, multicenter, randomized, partly double-blind, controlled trial to evaluate the safety and efficacy of convalescent serum (CP) or camostat mesylate with control or placebo in adult patients diagnosed with SARS-CoV-2 and high risk for moderate/severe COVID-19. Camostat mesylate acts as an inhibitor of the host cell serine protease TMPRSS2 and prevents the virus from entering the cell. Convalescent plasma (CP) represents another antiviral strategy in terms of passive immunization. The working hypothesis to be tested in the RES-Q HR study is that the early use of convalescent plasma (CP) or camostat mesylate (Foipan®) reduces the likelihood of disease progression to modified WHO stages 4b-8 in SARS-CoV-2 positive adult patients at high risk of moderate or severe COVID-19 progression.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| convalescent plasma (CP) | Experimental | Administration of 2 units of CP (neutralizing anti-SARS-CoV-2 antibody titer of at least 1:160) on day 1 |
|
| Standard of Care | Other | Standard of care allowed |
|
| Camostat Mesilate | Experimental | Tablets 600 mg per day in 3 doses over 7 days |
|
| Placebo camostat | Placebo Comparator | Placebo Tablets in 3 doses over 7 days (blinded) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Convalescent plasma | Biological | transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160) |
|
| Measure | Description | Time Frame |
|---|---|---|
| WHO ordinal Covid-19 scale up to day 28 | The primary endpoint of the study is the number of individuals whose clinical status is on the COVID-19 modified WHO ordinal scale ≥ 4b up to and including day 28 | up to and including day 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative number WHO categories 4b-8 | Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 4b-8 | day 8, day 14, day 56 and day 90 |
| Cumulative number WHO categories 3-4a |
Not provided
Inclusion Criteria:
Individuals (female, male, diverse) ≥ 18 years with SARS-CoV-2 infection, confirmed by PCR before study enrollment
SARS-CoV-2 positive PCR ≤ 3 days old (date of NP swab)
Presence of ≥ 1 SARS-CoV-2 typical symptom (fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration <= 3 days.
Ability to provide written informed consent
Presence of at least one of the following criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Verena Keitel-Anselmino, Prof.Dr.med. | Klinik für Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum Düsseldorf | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Abteilung Infektiologie Klinik für Innere Medizin II Department Innere Medizin Universitätsklinikum Freiburg | Freiburg im Breisgau | Baden-Wurttemberg | 79106 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34001215 | Derived | Keitel V, Jensen B, Feldt T, Fischer JC, Bode JG, Matuschek C, Bolke E, Budach W, Plettenberg C, Scheckenbach K, Kindgen-Milles D, Timm J, Muller L, Kolbe H, Stohr A, Calles C, Hippe A, Verde P, Spinner CD, Schneider J, Wolf T, Kern WV, Nattermann J, Zoufaly A, Ohmann C, Luedde T; RES-Q-HR Trial Team. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is a multicenter trial that will be conducted in approx. 10 - 15 centers in Germany.
At each center, patients will be randomized into four groups: two treatment groups and two control groups. The randomization rate in this study is two to one (2:1) in favor to therapy, i.e.
included patients have twice the chance to receive interventional therapy than placebo / SoC.
Not provided
Not provided
The camostat mesylate and its placebo group will be double blinded while the CP and its placebo will be open label.
| Camostat Mesilate | Drug | Tablets over 7 days, daily dose of 600 mg split into 3 doses |
|
| Placebo for Camostat Mesilate | Drug | Placebo Tablets over 7 days, split into 3 doses |
|
| Standard of Care (SoC) | Other | Control Arm for convalescent plasma (CP) |
|
Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 3-4a
| day 8, day 14, day 28, day 56 and day 90 |
| Not hospitalized | Cumulative number of participants not hospitalized at day 90 | at day 90 |
| All-cause mortality | All-cause mortality at day 90 | at day 90 |
| Reinfection | Number of patient with SARS-CoV-2 reinfection up to day 90 | up to day 90 |
| Secondary sclerosing cholangitis (SSC) | Number of patient with secondary sclerosis cholangitis at day 90 | at day 90 |
| chronic pulmonary disease as sequelae from COVID-19 | Number of patient with COVID-19 associated chronic pulmonary disease | at day 90 |
| patients with remdesivir treatment | The proportion of patients with remdesivir therapy | up to day 90 |
| COVID-19 WHO status of patients at start of remdesivir treatment | The clinical status on the WHO COVID-19 ordinal scale of at the start of remdesivir treatment WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death | up to day 90 |
| patients with dexamethasone treatment | The proportion of patients on dexamethasone therapy | up to day 90 |
| COVID-19 WHO status of patients at start of dexamethasone treatment | The clinical status on the WHO COVID-19 ordinal scale of at the start of dexamethasone treatment WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death | up to day 90 |
| resolution of COVID-19 symptoms | Time to resolution of COVID-19 related symptoms (e.g. fever) | until day of resolution up to day 90 |
| negative SARS-CoV-2-PCR test | Time to first negative SARS-CoV-2-PCR (polymerase chain reaction) | until day of first negative test up to day 90 |
| Oxygen therapy | Duration of oxygen therapy (in days) | number of days with oxygen therapy up to day 90 |
| COVID-19 pneumonia | Frequency of occurrence of COVID-19 pneumonia | up to day 90 |
| Percentage of participants requiring mechanical ventilation | Percentage of participants in each group with need for mechanical ventilation | up to day 90 |
| Number of ventilation days per participant up to day 90 | Number of ventilation days per participant up to day 90 | up to day 90 |
| hospital stay and intensive care | Duration of hospital stay (in days), duration in intensive care/intermediate care (IMC) (in days) | up to day 90 |
| Mortality | All-cause mortality at day 28 | at day 28 |
| SAEs | Cumulative incidence of Serious Adverse Events (SAE) per group within 90 days follow up | up to day 90 |
| Grade 3/4 AEs | Cumulative incidence of grade 3/4 Adverse Events (AE) per group | up to day 90 |
| SARS-CoV-2 antibody IgA concentrations | SARS-CoV-2 antibody concentrations (IgA in g/l) in serum on day 8, day 14, day 90 | on day 8, day 14, day 90 |
| SARS-CoV-2 antibody IgG concentrations | SARS-CoV-2 antibody concentrations (IgG in g/l) in serum on day 8, day 14, day 90 | on day 8, day 14, day 90 |
| SARS-CoV-2 neutralizing antibody titers | SARS-CoV-2 neutralizing antibody titers in serum on day 8, day 14, day 90 | on day 8, day 14, day 90 |
| Plasma treatment screening failures | Number of screening failures due to the lack of a suitable plasma preparation | up to day 8 (End of treatment) |
| Klinik und Poliklinik für Innere Medizin II Klinikum rechts der Isar Technische Universität München | München | Bavaria | 81675 | Germany |
| Universitätsklinikum Frankfurt Medizinische Klinik 2: Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie/HIV | Frankfurt am Main | Hesse | 60590 | Germany |
| Klinikum Dortmund | Dortmund | North Rhine-Westphalia | 44137 | Germany |
| Universitätsklinikum Düsseldorf Klinik für Hepatologie und Infektiologie | Düsseldorf | North Rhine-Westphalia | 40225 | Germany |
| Universitätsklinikum Essen | Essen | North Rhine-Westphalia | 45147 | Germany |
| ID | Term |
|---|---|
| D018352 | Coronavirus Infections |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C034532 | camostat |
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided